Edwards Lifesciences EW has just entered Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly chart. While the stock's setup doesn't necessarily point to a bearish outlook, the structure suggests that sluggish, range-bound price action could dominate through early 2027. Tracking Edwards Lifesciences' Adhishthana Himalayan Formation According to the Adhishthana Principles, a stock typically breaks out of its Cakra formation in Phase 9, triggering a strong upward move. This marks the star ...

Core Insights - Edwards Lifesciences reported strong second-quarter 2025 earnings, surpassing revenue and earnings expectations, primarily driven by growth in heart valve therapies [1][2][3] Financial Performance - The company achieved sales of $1.53 billion, exceeding the consensus estimate of $1.49 billion and falling within management's guidance of $1.45 billion to $1.53 billion [2] - Sales grew by 11.9%, or 10.6% when adjusted, with all product groups showing strength [3] - Adjusted earnings were reported at 67 cents per share, beating the consensus of 62 cents and management's guidance of 59 to 65 cents [3] Segment Performance - Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.1 billion, marking an increase of 8.9%, or 7.8% on a constant currency basis [4] - Transcatheter Mitral and Tricuspid Therapies (TMTT) segments reported sales of $134.5 million, demonstrating a year-over-year growth of 61.9%, or over 57.1% on a constant currency basis [5] - Surgical segment global sales reached $267 million, an increase of 7.7% year-over-year, or 6.8% on a constant currency basis [5] Guidance and Outlook - The company raised its full-year sales guidance from $5.70 billion to $6.10 billion to a new range of $5.90 billion to $6.10 billion, compared to the consensus of $5.91 billion [6] - Adjusted earnings guidance for fiscal 2025 is affirmed at $2.40 to $2.50 per share, with third-quarter adjusted earnings forecasted at 54 to 60 cents [7] - TAVR underlying growth rate guidance is increased to 6% to 7%, with sales guidance for TAVR set at $4.3 billion to $4.5 billion [8] Analyst Insights - Goldman Sachs views the second quarter as a turning point for the company, expecting steady double-digit revenue growth [9] - Analysts predict that Edwards will return to strong performance, with revenue growth over 10% and operating margins above 30% [11] - Various analysts have raised their price forecasts for Edwards Lifesciences, with Deutsche Bank increasing its target from $85 to $94, and Barclays raising its forecast from $90 to $95 [12][13][14]

Core Insights - Edwards Lifesciences Corporation reported better-than-expected second-quarter financial results, with adjusted earnings of 67 cents per share, surpassing market estimates of 62 cents per share [1] - Quarterly sales reached $1.532 billion, exceeding expectations of $1.488 billion [1] - The company affirmed FY2025 adjusted EPS guidance of $2.40-$2.50 and raised FY2025 sales guidance from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion [1] Financial Performance - The CEO highlighted strong second-quarter results with double-digit sales growth, attributing confidence in the full-year outlook to better-than-expected first-half performance and various catalysts across the portfolio [2] - Edwards Lifesciences shares increased by 5.1%, trading at $79.51 following the earnings announcement [2] Analyst Ratings and Price Targets - Baird analyst David Rescott maintained a Neutral rating and raised the price target from $78 to $79 [5] - Deutsche Bank analyst Pito Chickering maintained a Buy rating and increased the price target from $85 to $94 [5] - Evercore ISI Group analyst Vijay Kumar maintained an In-Line rating and raised the price target from $77 to $80 [5]

Core Insights - Edwards Lifesciences Corporation reported Q2 2025 adjusted EPS of 67 cents, exceeding estimates by 8.1% and reflecting an 8.1% year-over-year increase [1] - Total sales reached $1.53 billion, up 11.7% year-over-year, surpassing estimates by 2.7% [2] - The company raised its 2025 sales growth forecast to 9-10% and adjusted EPS guidance to the high end of $2.40-$2.50 [11][12] Q2 Sales Performance - Sales from Transcatheter Aortic Valve Replacement (TAVR) totaled $1.10 billion, an increase of 8.9% year-over-year [3] - Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $134.5 million, up 61.9% from the previous year [5] - Surgical Structural Heart segment sales were $267 million, reflecting a 7.7% year-over-year increase [6] Margin and Expense Analysis - Gross profit was $1.19 billion, up 8.6% year-over-year, but gross margin contracted by 236 basis points to 77.5% due to a 25% rise in cost of sales [7] - SG&A expenses rose 12.2% year-over-year to $502 million, while R&D expenditures increased by 1.6% to $276.2 million [9] Cash Position and Debt - The company ended Q2 with cash and cash equivalents of $3.00 billion, down from $3.10 billion at the end of Q1 2025, with total debt remaining around $600 million [10] Market Dynamics and Innovations - Clinical discussions around EARLY TAVR trial data are enhancing patient management for severe aortic stenosis in the U.S. [4] - The exit of a competitor in Europe has positively impacted Edwards' market share [4] - The SAPIEN M3 mitral valve replacement system received CE Mark approval, strengthening the TMTT portfolio [14]

Core Insights - Edwards Lifesciences reported $1.53 billion in revenue for Q2 2025, a year-over-year decline of 6.1% with an EPS of $0.67 compared to $0.70 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $1.49 billion, resulting in a surprise of +2.85%, while the EPS also surpassed expectations by +8.06% [1] Revenue Performance - Net Sales in Europe reached $378.2 million, exceeding the average estimate of $353.07 million, reflecting a year-over-year increase of +12.7% [4] - Net Sales outside the United States were $642.5 million, surpassing the average estimate of $621.76 million, with a year-over-year change of +12.9% [4] - Net Sales in the United States amounted to $889.7 million, above the average estimate of $865.54 million, showing an increase of +8.9% year-over-year [4] - Net Sales in Japan were $95.3 million, slightly below the average estimate of $105.11 million, but still representing a +9% year-over-year change [4] - Net Sales in the Rest of the World reached $169 million, exceeding the average estimate of $163.59 million, with a year-over-year increase of +15.7% [4] Product Group Performance - Net Sales for Transcatheter Mitral and Tricuspid Therapies were $134.5 million, surpassing the average estimate of $129.87 million, with a significant year-over-year increase of +62.1% [4] - Net Sales for Surgical Structural Heart products totaled $266.8 million, exceeding the average estimate of $259.33 million, reflecting a year-over-year change of +1% [4] - Net Sales for Transcatheter Aortic Valve Replacement reached $1.13 billion, above the average estimate of $1.1 billion, with a year-over-year increase of +8.9% [4] Stock Performance - Shares of Edwards Lifesciences have returned -0.1% over the past month, while the Zacks S&P 500 composite increased by +5.7% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Financial Data and Key Metrics Changes - The company reported total sales of $1,530 million for Q2 2025, reflecting a growth of 10.6% compared to the previous year, which was better than expected [9][10]. - Adjusted earnings per share (EPS) for the quarter was $0.67, while GAAP EPS was $0.57, which included a one-time charge related to external investments [26][27]. - The adjusted gross profit margin was 77.6%, down from 80% in the same period last year, attributed to increased manufacturing expenses and foreign exchange impacts [27][28]. Business Line Data and Key Metrics Changes - In the Transcatheter Aortic Valve Replacement (TAVR) segment, global sales reached $1,100 million, marking a 7.8% increase year-over-year [10][11]. - The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment saw sales of $133 million, growing 57% due to strong demand for PASCAL and EVOQUE technologies [18][19]. - Surgical Products Group reported global sales of $267 million, an increase of 6.8% compared to the prior year [24]. Market Data and Key Metrics Changes - TAVR growth was stable in both the U.S. and outside the U.S. (OUS), with a notable increase in Japan where sales grew in the mid-single digits [15][10]. - The exit of a competitor in Europe led to a rebalancing of market share, contributing modestly to sales growth [15][44]. - The company anticipates mid to high single-digit growth opportunities in TAVR, supported by recent approvals and guideline changes [16][10]. Company Strategy and Development Direction - The company introduced the "Sharpen Focus" strategy, targeting significant growth in structural heart therapies, particularly in aortic regurgitation and heart failure [8][9]. - The focus on a balanced portfolio across aortic, mitral, and tricuspid therapies is expected to position the company for long-term leadership [9]. - The company is raising its full-year 2025 sales growth guidance to 9% to 10%, reflecting confidence in its strategic initiatives and market position [10][33]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable growth, driven by a strong portfolio and upcoming catalysts [34][66]. - The management highlighted the importance of recent approvals for asymptomatic TAVR, which are expected to create multi-year growth opportunities [11][12]. - The company is optimistic about the impact of potential changes in CMS guidelines and the NCD on patient access and treatment volumes [61][62]. Other Important Information - The company announced the departure of Larry Wood, the leader of the TAVR team, who will be succeeded by Dan Lippis [16][17]. - The company is in the final stages of the regulatory review process for the acquisition of GenaValve, with expectations to close the deal in Q3 [33]. Q&A Session Summary Question: What drove the better-than-expected U.S. TAVR performance? - Management attributed the performance to a renewed focus on TAVR within the clinical community and the impact of early TAVR study data [36][38]. Question: What trends were observed outside the U.S.? - Management noted positive feedback from the rollout of the S3UR platform in Europe and emphasized the importance of addressing undertreatment in Japan [43][45]. Question: Why not raise EPS guidance further? - Management cited ongoing headwinds, particularly related to GenaValve, as a reason for caution despite strong Q2 performance [48][49]. Question: What is the expected impact of the NCD reopening? - Management expressed optimism that changes could streamline operator requirements, improving patient access and care [61][62]. Question: What is the outlook for the TMTT business, particularly EVOQUE? - Management reported strong physician and patient excitement around EVOQUE, with real-world outcomes aligning with clinical trial data [71][72].

Financial Data and Key Metrics Changes - The company reported total sales of $1,530 million for Q2 2025, reflecting a growth of 10.6% compared to the previous year, which was better than expected [8][9] - Adjusted earnings per share (EPS) for the quarter was $0.67, while GAAP EPS was $0.57, which included a one-time charge related to external investments [23][24] - The adjusted gross profit margin was 77.6%, down from 80% in the same period last year, attributed to increased manufacturing expenses and foreign exchange impacts [25][26] Business Line Data and Key Metrics Changes - TAVR sales reached $1,100 million, increasing by 7.8% year-over-year, with stable competitive positioning and pricing [9][10] - TMTT product group sales were $133 million, growing by 57%, driven by the success of PASCAL and EVOQUE technologies [16][17] - Surgical Products Group sales were $267 million, reflecting a 6.8% increase compared to the prior year, supported by positive procedure growth globally [21][22] Market Data and Key Metrics Changes - In the U.S., TAVR growth was bolstered by renewed clinical focus and recent approvals for asymptomatic indications, while international markets, particularly Japan and Europe, showed strong growth despite competitive challenges [10][13][42] - The exit of a competitor in Europe contributed to a modest market share rebalancing, positively impacting sales [13][40] Company Strategy and Development Direction - The company is focused on its "Sharpen Focus" strategy, targeting structural heart failure and aortic regurgitation, which are seen as significant growth opportunities [7][8] - The company is raising its full-year sales growth guidance to 9% to 10%, reflecting confidence in its product portfolio and market position [9][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about mid to high single-digit growth in TAVR, supported by recent approvals and evolving clinical guidelines [14][30] - The company is committed to advancing evidence for aortic stenosis patients and is confident in its ability to deliver significant value to patients and shareholders [31][62] Other Important Information - The company announced the departure of Larry Wood, the leader of the TAVR team, and Dan Lippis will assume leadership, ensuring continuity in the TAVR franchise [14][15] - The company is in the final stages of acquiring GenaValve, with expectations to close the deal in Q3 2025 [30][98] Q&A Session Summary Question: What drove better-than-expected U.S. TAVR performance? - Management noted a renewed focus on TAVR management and timely treatment of patients, driven by recent clinical data and approvals [34][36][39] Question: What are the trends outside the U.S.? - Management highlighted positive feedback from the rollout of the S3UR platform in Europe and ongoing efforts to expand therapy in Japan [40][42] Question: Why not raise EPS guidance further? - Management cited ongoing headwinds, particularly related to GenaValve, as a reason for cautious EPS guidance despite strong performance [45][46] Question: What is the impact of the competitor's exit on market share? - Management emphasized the importance of demonstrating the value of their technology and ensuring patient access to high-quality care following the competitor's exit [48][50] Question: When do you expect CMS to reopen the NCD? - Management expressed hope for a timely reopening of the NCD, emphasizing the need for coverage of asymptomatic patients and streamlined operator requirements [55][58] Question: What is the outlook for the TMTT business, particularly EVOQUE? - Management reported strong physician and patient excitement around EVOQUE, with real-world outcomes showing promise [67][70][72] Question: What are the long-term margin expectations? - Management indicated a focus on annual operating profit margin expansion rather than setting specific targets, aiming for consistent growth [75][76]

[Financial and Operational Highlights](index=1&type=section&id=Financial%20and%20Operational%20Highlights) [Second Quarter 2025 Performance](index=1&type=section&id=Second%20Quarter%202025%20Performance) Edwards Lifesciences reported strong double-digit sales growth in the second quarter of 2025, with total sales reaching $1.53 billion, an 11.9% increase (10.6% adjusted), this growth was driven by strong performance across all product groups, particularly TMTT which grew over 60%, and adjusted EPS for the quarter was $0.67 Q2 2025 Key Financial Metrics | Metric | Value | Growth (YoY) | Adjusted Value | Adjusted Growth (YoY) | | :--- | :--- | :--- | :--- | :--- | | **Total Sales** | $1.53 billion | 11.9% | $1.53 billion | 10.6% | | **TAVR Sales** | $1.1 billion | 8.9% | $1.13 billion | 7.8% (Constant Currency) | | **TMTT Sales** | $134.5 million | 61.9% | $133.0 million | 57.1% | | **Diluted EPS** | $0.57 | - | $0.67 | - | - Key operational and clinical achievements in Q2 include: - The SAPIEN platform became the only TAVR approved for asymptomatic patients in both the U.S. and Europe - 10-year data from the PARTNER II study confirmed the long-term durability of Edwards TAVR - The SAPIEN M3 system received CE Mark approval, enhancing the TMTT portfolio[4](index=4&type=chunk) [Full Year 2025 Outlook](index=1&type=section&id=Full%20Year%202025%20Outlook) Buoyed by strong first-half performance, the company has raised its full-year 2025 guidance, projecting total sales growth of 9-10% (up from 8-10%) and increased TAVR sales growth, with adjusted EPS now expected at the high end of the $2.40 to $2.50 range - CEO Bernard Zovighian expressed confidence in the full-year outlook, citing better-than-expected first-half performance and multiple catalysts across the product portfolio[3](index=3&type=chunk) Updated Full-Year 2025 Guidance | Metric | Previous Guidance | Updated Guidance | | :--- | :--- | :--- | | **Total Sales Growth** | 8-10% | 9-10% | | **Total Sales** | - | $5.9B - $6.1B | | **TAVR Sales Growth** | 5-7% | 6-7% | | **TAVR Sales** | - | $4.3B - $4.5B | | **Adjusted EPS** | $2.40 - $2.50 | High-end of $2.40 - $2.50 | - For the third quarter of 2025, the company projects total sales between $1.46 and $1.54 billion and adjusted EPS of $0.54 to $0.60[17](index=17&type=chunk) [Business Segment Performance](index=2&type=section&id=Business%20Segment%20Performance) [Transcatheter Aortic Valve Replacement (TAVR)](index=2&type=section&id=Transcatheter%20Aortic%20Valve%20Replacement%20(TAVR)) The TAVR segment reported sales of $1.1 billion, growing 8.9% (7.8% constant currency) in Q2, driven by continued SAPIEN technology adoption, a renewed focus on timely severe aortic stenosis treatment in the U.S., and market share gains in Europe following a competitor's exit TAVR Q2 2025 Performance | Metric | Value | Growth (YoY) | Constant Currency Growth (YoY) | | :--- | :--- | :--- | :--- | | **Sales** | $1.1 billion | 8.9% | 7.8% | - In the U.S., the EARLY TAVR trial data is encouraging more timely treatment of patients with severe aortic stenosis (AS) - In Europe, a competitor's exit led to a rebalancing of market share, modestly benefiting Edwards' sales - In Japan, TAVR sales grew in the mid-single digits, an improvement from the previous quarter[6](index=6&type=chunk)[7](index=7&type=chunk) [Transcatheter Mitral and Tricuspid Therapies (TMTT)](index=2&type=section&id=Transcatheter%20Mitral%20and%20Tricuspid%20Therapies%20(TMTT)) The TMTT segment achieved impressive growth, with sales reaching $134.5 million (61.9% year-over-year increase), fueled by strong PASCAL technology adoption, a successful EVOQUE system launch, and portfolio strengthening via CE Mark approval for the SAPIEN M3 mitral valve replacement system TMTT Q2 2025 Performance | Metric | Value | Growth (YoY) | Adjusted Growth (YoY) | | :--- | :--- | :--- | :--- | | **Sales** | $134.5 million | 61.9% | 57.1% | - Strong adoption of PASCAL technology continues in new and existing centers - The EVOQUE system's commercial launch is progressing well in the U.S. and Europe, with high demand - The SAPIEN M3 mitral valve system received CE Mark approval in Q2, receiving positive early clinician feedback[9](index=9&type=chunk)[10](index=10&type=chunk) [Surgical](index=2&type=section&id=Surgical) The Surgical segment posted Q2 sales of $267 million (7.7% increase), supported by positive global procedure trends for its premium RESILIA tissue portfolio, including INSPIRIS, MITRIS, and KONECT technologies, with the KONECT aortic valved conduit also receiving CE Mark approval in Europe during the quarter Surgical Q2 2025 Performance | Metric | Value | Growth (YoY) | Constant Currency Growth (YoY) | | :--- | :--- | :--- | :--- | | **Sales** | $267 million | 7.7% | 6.8% | - The company's KONECT aortic valved conduit received CE Mark approval in Europe during the second quarter[12](index=12&type=chunk) [Detailed Financial Results](index=3&type=section&id=Detailed%20Financial%20Results) [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) For Q2 2025, net sales increased to $1.53 billion from $1.37 billion, gross profit rose to $1.19 billion despite a gross margin decline to 77.5%, and operating income increased to $411.2 million, though net income from continuing operations decreased to $335.9 million primarily due to higher income taxes and an impairment loss Q2 Statement of Operations (in millions) | Account | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | **Net sales** | $1,532.2 | $1,369.4 | +11.9% | | **Gross profit** | $1,187.8 | $1,093.9 | +8.6% | | **Operating income, net** | $411.2 | $366.5 | +12.2% | | **Net income from continuing operations** | $335.9 | $364.0 | -7.7% | [Operating Expenses and Margins](index=3&type=section&id=Operating%20Expenses%20and%20Margins) The Q2 gross profit margin was 77.5% (down from 79.9%) due to manufacturing expenses and foreign exchange, while SG&A expenses rose to $502 million (32.8% of sales) and R&D expenses were $276 million (18.0% of sales), reflecting strategic investment prioritization, resulting in an adjusted operating margin of 28.2% Q2 2025 Key Margins and Expenses | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Gross Profit Margin** | 77.5% | 79.9% | | **SG&A (% of Sales)** | 32.8% | 32.7% | | **R&D (% of Sales)** | 18.0% | 19.8% | | **Operating Profit Margin** | 26.8% | 26.8% | | **Adjusted Operating Profit Margin** | 28.2% | 27.4% | - The year-over-year decrease in gross margin was driven by additional manufacturing expenses for new therapies and foreign exchange effects[13](index=13&type=chunk) [Balance Sheet and Cash Position](index=3&type=section&id=Balance%20Sheet%20and%20Cash%20Position) As of June 30, 2025, Edwards Lifesciences maintained a strong liquidity position with approximately $3 billion in cash and cash equivalents and total debt of approximately $600 million Key Balance Sheet Items (as of June 30, 2025) | Item | Amount | | :--- | :--- | | **Cash and cash equivalents** | ~$3 billion | | **Total debt** | ~$600 million | [Non-GAAP Reconciliation](index=6&type=section&id=Non-GAAP%20Reconciliation) The company uses non-GAAP measures to exclude items like certain litigation expenses, amortization, separation costs, and impairment losses, providing a clearer view of core operational performance, which for Q2 2025 resulted in a non-GAAP adjusted EPS of $0.67 from a GAAP diluted EPS of $0.57 - Management uses non-GAAP measures for internal decision-making and to enhance comparability with industry peers by excluding items that do not reflect core operational activities[27](index=27&type=chunk)[28](index=28&type=chunk) Q2 2025 GAAP to Non-GAAP EPS Reconciliation | Description | Per Share Amount | | :--- | :--- | | **GAAP Diluted EPS from Continuing Operations** | **$0.57** | | Certain litigation expenses | $0.03 | | Separation costs | $0.01 | | Loss on impairment | $0.06 | | **Adjusted Diluted EPS** | **$0.67** | [Sales by Product Group and Region](index=9&type=section&id=Sales%20by%20Product%20Group%20and%20Region) On a constant currency basis for Q2 2025, TAVR grew 7.8%, TMTT grew 57.1%, and Surgical grew 6.8%, while regionally, the U.S. saw 10.1% adjusted growth and sales outside the U.S. grew 11.3% on a constant currency basis, led by strong performance in the Rest of World category Q2 2025 Constant Currency Growth (YoY) | Category | Constant Currency Growth Rate | | :--- | :--- | | **Product Groups** | | | TAVR | 7.8% | | TMTT (Adjusted) | 57.1% | | Surgical | 6.8% | | **Regions (Adjusted)** | | | United States | 10.1% | | Europe | 9.6% | | Japan | 4.2% | | Rest of World | 19.5% |

Core Viewpoint - Edwards Lifesciences Corp. is set to report its second-quarter 2025 results on July 24, with expectations of revenue and earnings declines compared to the previous year [1][2]. Q2 Estimates - The Zacks Consensus Estimate for revenues is $1.49 billion, indicating an 8.9% decline from the prior year's figure [2]. - The estimate for net earnings is 62 cents per share, reflecting an 11.4% decrease from the year-ago reported figure [2]. Estimate Revision Trend - Earnings estimates have remained unchanged at 62 cents per share over the past 60 days, indicating stability in expectations ahead of the earnings announcement [3]. Factors at Play - The Transcatheter Aortic Valve Replacement (TAVR) segment is expected to perform well in the U.S. due to the SAPIEN 3 Ultra RESILIA platform, with a projected revenue of $1.09 billion, representing a 5.2% year-over-year increase [4][5]. - The TMTT segment is anticipated to show significant growth, with revenues estimated at $130.4 million, a 57.1% improvement from the previous year, driven by the PASCAL and EVOQUE systems [6][8]. Segment Performance - The Surgical Structural Heart segment is expected to report revenues of $263.1 million, suggesting a modest 6.2% rise from the year-ago quarter, supported by the global adoption of the RESILIA portfolio [10][11]. - The commercial launch of the EVOQUE tricuspid replacement system is likely to have progressed well, aided by Medicare coverage [7]. Earnings Whispers - Edwards has an Earnings ESP of 0.00%, indicating no advantage in beating estimates this quarter [12]. - The company currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to other stocks [13].

Core Insights - Analysts forecast Edwards Lifesciences (EW) to report quarterly earnings of $0.62 per share, reflecting a year-over-year decline of 11.4% [1] - Expected revenues are projected at $1.49 billion, indicating a decrease of 8.9% compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [3] Key Metrics Projections - Net Sales by Product Group for Transcatheter Mitral and Tricuspid Therapies is estimated at $129.87 million, a change of +56.5% from the year-ago quarter [5] - Net Sales by Product Group for Surgical Structural Heart is projected at $259.33 million, reflecting a decrease of -1.9% from the previous year [5] - Net Sales by Product Group for Transcatheter Aortic Valve Replacement is expected to be $1.10 billion, showing an increase of +5.7% year-over-year [6] - Net Sales in Europe are anticipated to reach $353.07 million, indicating a change of +5.2% from the prior-year quarter [6] Regional Sales Expectations - Net Sales Outside of the United States are projected at $621.76 million, reflecting a change of +9.3% from the year-ago quarter [7] - Net Sales in the United States are expected to be $865.54 million, indicating a change of +6% year-over-year [7] - Net Sales in Japan are forecasted to reach $105.11 million, showing an increase of +20.3% from the prior-year quarter [7] - Net Sales for the Rest of World are projected at $163.59 million, reflecting a change of +12% from the previous year [8] Stock Performance - Edwards Lifesciences shares have increased by +3.6% in the past month, compared to the Zacks S&P 500 composite's +5.4% [8] - With a Zacks Rank 2 (Buy), EW is expected to outperform the overall market performance in the near term [8]